Research Paper Volume 15, Issue 8 pp 3035—3051

TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process

class="figure-viewer-img"

Figure 6. TYRO3 regulated the effect of ENO1 and the process of EMT in CRC cells. (A, B) Correlation analysis of TYRO3 and ENO1 gene expression levels in (A) colon cancer and (B) rectal cancer patients in TCGA datasets via GEPIA platform. (C) Western blot showing TYRO3, ENO1 and β-Actin protein levels in H-DR and T-DR cells transfected with TYRO3-shRNA or negative control. (D) Immunoblot result of H-DR and T-DR semi-quantified by ImageJ. (E) Comparisons of relative ATP levels in H-DR and T-DR cells transfected with TYRO3-shRNA or negative control. (F) Western blot showing TYRO3, E-Cadherin, Vimentin and β-Actin protein levels in H-DR and T-DR cells transfected with TYRO3-shRNA or negative control. (G) Immunoblot result of H-DR and T-DR semi-quantified by ImageJ. Abbreviations: NC: negative control; KD: TYRO3-shRNA. *P < 0.05, **P < 0.01, ***P < 0.001.